 CAMBRIDGE, Mass., Nov. 01, 2022 GLOBE NEWSWIRE -- Voyager Therapeutics, Inc. Nasdaq: VYGR, a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus AAV capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results. 